Opinion|Videos|April 29, 2026
Future Directions in Follicular Lymphoma Management
Author(s)Loretta J. Nastoupil, MD, Amitkumar Mehta, MD
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss future research to watch in follicular lymphoma.
Advertisement
Episodes in this series
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, outline key unanswered questions and future research priorities in follicular lymphoma management. Nastoupil discusses ongoing studies aimed at refining sequencing strategies and optimizing integration of bispecific antibodies and cellular therapies. Mehta concludes by emphasizing the need for continued investigation into biomarkers and comparative data to better personalize treatment approaches.
Advertisement
Related to this article
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.
Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
3
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
4
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
5